# Wave 3 Challenge Round + Gate 3 Internal-Consistency Check

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Owner: Research Director · Conducted: 2026-08-31, after `40_SYNTHESIS/00`–`08` were drafted

Per Runbook §30, applied here specifically to the freshly-drafted `40_SYNTHESIS/` content (not a
repeat of the Wave 2 Challenge Round's source-level review, which remains valid and is referenced
throughout the synthesis). Findings below were caught by re-reading the synthesis adversarially
against `02_SOURCE-INVENTORY.md` immediately after drafting; corrections were applied in place.

## Findings caught and corrected during this pass

1. **Guideline angle — misattribution caught**: `00_executive-synthesis.md` originally attributed
   the four-tier primary-prevention LDL-C targets (<100/<115/<130/<160 mg/dL) to *both* citation #29
   and #35. Only #35 (2022 Taiwan primary-prevention guideline) actually carries that four-tier
   structure per `02_SOURCE-INVENTORY.md` row 63; #29 (2022 secondary-prevention/high-risk update)
   recommends by baseline LDL-C/clinical status without a single absolute number, per row 57.
   **Corrected in `00_executive-synthesis.md`.**
2. **Guideline angle — inconsistent verification-rigor caught**: `06_adherence-residual-risk.md`
   stated ESC 2025's Lp(a) threshold (>50 mg/dL / >105 nmol/L) without the same "unverified against
   primary text, sourced from PI topic notes" caveat already correctly applied to the Taiwan STS
   2026 claim in `00`/`02` — both T-007 and T-005 are `BLOCKED_FOR_SOURCE` and both specific claims
   trace only to `pitavastatin topic.md`'s paraphrase, not independently confirmed primary text.
   **Corrected in `06_adherence-residual-risk.md`** — this is exactly the kind of inconsistent
   scrutiny the challenge-round discipline exists to catch: the same caution applied to one claim
   must be applied to structurally identical claims elsewhere in the same document set.
3. **Methods angle — verification-layer conflation caught**: `02_guideline-risk-positioning.md`'s
   comparison table listed citation #27's risk-tier LDL-C thresholds (130/115/100/70/55 mg/dL)
   without noting that these specific numbers trace to `Tonvasca_2026.md`'s own reproduced
   flowchart, not to an independent re-check of #27's primary full text — a different, weaker
   verification layer than #27's own bibliographic (DOI/author/journal) verification. **Corrected**
   to distinguish citation-level verification from content-level verification explicitly.

## Checks that passed (no correction needed)

- **Trials angle**: REPRIEVE (T-015) / REAL-CAD (T-016) are consistently flagged "pitavastatin
  monotherapy, not FDC" everywhere they appear (`00`, `04`, `08`) — the project's top-flagged
  overclaim risk is correctly guarded throughout the new synthesis content, not just in the
  Wave 2 Challenge Round document itself.
- **Trials angle**: the "add ezetimibe or double the statin?" comparison is consistently described
  as not-formally-tested (descriptive point estimate only) in `00`, `03`, and `08` — no drift toward
  presenting it as a significant finding anywhere in the synthesis.
- **Safety angle**: no instance of "does not cause diabetes" or "no DDI" language found anywhere in
  `40_SYNTHESIS/00`–`08` (grep-checked); the FDC-specific CKD dosing gap is consistently flagged as
  the project's highest-stakes safety gap in `00`, `05`, and `07`.
- **Methods angle**: every `INDIRECT EVIDENCE`/`OBSERVATIONAL EVIDENCE`/`MECHANISTIC SUPPORT` tag
  used in `01_claim-evidence-matrix.md` and `08_traceability-table.md` traces to a tag already
  present in `02_SOURCE-INVENTORY.md` — no new, un-sourced hierarchy classification was introduced.
- **Cross-file consistency (Gate 3 requirement)**: numbers appearing in more than one synthesis file
  (e.g., HIJ-PROPER's HR 0.89/95% CI/P-value in both `00` and `04`; REPRIEVE's MACE HR 0.65 in `00`,
  `04`, and `08`; the Sydhom framing sentence in `00` and `01`) were checked for exact match across
  occurrences — all consistent, no drift between files.
- **Citation-ID typo check**: `grep -rn "T-033"` across `40_SYNTHESIS/` returned no matches (an
  earlier draft risk, since citation #33 and source-ID T-033 could easily be confused) — the correct
  `#33` form is used consistently.

## Gate 3 determination

**Gate 3: PASSED.** All nine required `40_SYNTHESIS/` deliverables are present
(`00`–`08`), internally consistent with each other and with `02_SOURCE-INVENTORY.md`/
`03_DECISION-LOG.md`, and the three self-caught issues above were corrected in place before this
determination. No manuscript/slide content was drafted (out of scope this wave, per PI directive).
No PDF or parsed full text is referenced from within `40_SYNTHESIS/` beyond citation IDs and
short quoted figures — full provenance stays in `02_SOURCE-INVENTORY.md` and the specialists' own
`10_DATA/`/`20_EVIDENCE/`/`30_METHODS/` paths.

**Next step per PI directive**: proceed automatically to Wave 4 — spawn a sonnet independent-auditor
session, read-only except `99_FINAL-QA.md`, to run the Final QA Checklist (Runbook §35,
`CLAUDE.md` §14.4) against the full repository including this synthesis.
